GSK has applied to the European Medicines Agency to expand use of its respiratory syncytial virus (RSV) vaccine to adults ...

GSK (LSE:GSK) announced that the European Medicines Agency accepted its regulatory application to expand the use of its RSV ...

London: GSK plc has announced that the European Medicines Agency (EMA) has accepted the company's regulatory application to ...

Drugmaker GSK said on Friday that its RSV vaccine, Arexvy, has been accepted for regulatory review by the European Medicines ...

Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health around ...

The Food and Drug Administration expanded the approval of Moderna’s RSV vaccine on Thursday, extending the license to include ...

After nearly 25 years with Sanofi, Sanjay Gurunathan, M.D., has left for GSK, where he will lead vaccine and infectious ...

OPEN The FTSE 100 was expected to open 38.4 points lower ahead of the bell on Friday after closing 0.23% higher in the ...

GSK said on Friday the European Medicines Agency had accepted the drugmaker’s application to expand the use of ...

RESVIA is now authorized for use in adults aged 18–59 years with an increased risk of respiratory syncytial virus-related ...

GSK said on Friday the European Medicines Agency had accepted the drugmaker's application to expand the use of its ...

GSK seeks EU approval for RSV vaccine for younger adults EU decision on expanded use expected by first half of 2026 June 13 (Reuters) - GSK (GSK.L), opens new tab has applied to the European ...